TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00057408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine (Zyprexa)
Description: Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT04538079

Intervention type: DEVICE
Intervention: Multimodal objective non-invasive Monitoring
Description: Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)

Intervention type: DEVICE
Intervention: Multimodal objective non-invasive Monitoring
Description: Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
Study: NCT02077400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephazolin
Description: Cephazolin
Study: NCT03465995

Intervention type: DEVICE
Intervention: NKI i-PAS Diagnostic Protocol
Description: The NKI i-PAS:~The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment.
Study: NCT00597415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: celecoxib 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00783458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate Nasal Spray
Description: One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate Nasal Spray
Description: One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal spray
Description: One dose (2 sprays in each nostril) of fluticasone nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal spray
Description: One dose (2 sprays in each nostril) of fluticasone nasal spray
Study: NCT00558181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, methylprednisolone
Description: Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
Study: NCT00418574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abagovomab
Description: 2 mg/ml SC (subcutaneously)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg/ml SC (subcutaneously)
Study: NCT04672122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Cathodal tDCS will be applied for 20 mins.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Cathodal tDCS will be applied for 20 mins.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Cathodal tDCS will be applied for 20 mins.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Cathodal tDCS will be applied for 20 mins.
Study: NCT03240783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral Tablet
Description: Dexamethasone Oral Tablet: 15 day taper dosing is: days 1-5 8mg (4mg bd) , days 6-10 4 mg (2mg bd), and days 11-15 2 mg (1mg bd). The dexamethasone is over-encapsulated in a gelatine capsule that is identical to the placebo capsule in appearance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Injection and/or oral placebo
Description: The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Injection and/or oral placebo
Description: The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
Study: NCT03823053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Core Stabilization Training
Description: Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. In addition, the training group received core stabilization exercises for multifidus, transversus abdominis, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and pelvic floor muscles.Exercises will be applied 1 sets of 10 repetitions and once a day.
Study: NCT00181207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic vest

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo pneumatic vest
Study: NCT02581696

Intervention type: DRUG
Group type: OTHER
Intervention: Lafutidine
Description: Lafutidine 10mg, 1 tablet, bid

Intervention type: DRUG
Group type: OTHER
Intervention: Irsogladine maleate
Description: Irsogladine maleate 2mg, 2 tablet, qd
Study: NCT02053753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab CP4
Description: Denosumab produced by a process referred to as CP4, administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab CP2
Description: Denosumab produced by a process referred to as CP2, administered subcutaneously.
Study: NCT02203487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIF 1149 BS - single rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00712465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Extended Release tablet, repeated administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Extended Release tablet, repeated administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Tablet, repeated administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Tablet, repeated administration
Study: NCT04129788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 5 milligram
Description: three doses taken, one per day on three consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: three doses taken, one per day on three consecutive days
Study: NCT01617057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiludronic acid
Description: 400 mg / day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg / day for 3 month
Study: NCT03246113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral alkylating agent with demonstrated antitumor activity.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
Study: NCT02076828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferro Sanol® sp
Description: The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Santafer® sp.
Description: The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferro Zinc® sp
Description: The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Study: NCT03684915

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotary files
Description: using rotary files in cleaning root canals of infected primary molars

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotary files
Description: using rotary files in cleaning root canals of infected primary molars
Study: NCT02439320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matches lasmiditan doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matches lasmiditan doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matches lasmiditan doses)
Study: NCT04564612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered as specified in the treatment arm
Study: NCT01959620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-Session Exposure Therapy
Description: One exposure therapy session lasting one hour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-Session Exposure Therapy
Description: Three exposure therapy sessions lasting one hour each, delivered one week apart
Study: NCT03240783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Injection and/or oral placebo
Description: The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
Study: NCT01100099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten challenge.
Description: The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
Study: NCT02928510

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo biospecimen collection

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Undergo colonoscopy
Study: NCT03240783

Intervention type: OTHER
Group type: OTHER
Intervention: Sham Injection and/or oral placebo
Description: The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
Study: NCT02928510

Intervention type: PROCEDURE
Intervention: Colposcopic Biopsy
Description: Undergo colposcopic biopsy

Intervention type: DRUG
Intervention: Idelalisib
Description: Given PO

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Physical Examination
Description: Undergo physical examination

Intervention type: PROCEDURE
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy
Study: NCT02302651

Intervention type: DEVICE
Group type: OTHER
Intervention: MR guided High Intensity focused ultrasound
Description: High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
Study: NCT04068103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Give IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo active surveillance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo active surveillance
Study: NCT04235244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermo mechanical device
Description: The thermomechanical-analgesia device will be placed and operated 30 seconds before the injection into the abdominal area,and injection will be applied by sliding the device to the side of the selected region during the injection,
Study: NCT03833765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+XCM
Description: After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF alone
Description: Coronally Advanced Flap procedure alone was performed to treat multiple recession defects
Study: NCT00773344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanespimycin
Description: Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)
Study: NCT02734784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Photodynamic Therapy
Description: After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
Study: NCT00413283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
Study: NCT04235244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local coolant spray
Description: Coolant spray will be applied to the abdominal area for 5 seconds at a distance of 15 cm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ıce battery
Description: abdominal bölgeye uygulamadan önce ve sonra 5 dk. lokal soğuk uygulama
Study: NCT03646994

Intervention type: DRUG
Intervention: Crizotinib
Description: Crizotinib Cap 250 mg po bid
Study: NCT03337399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped PC
Description: Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Integrated PC
Description: Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer
Study: NCT02844296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about exercise
Description: Video about short-bout exercise will be played for the participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App about exercise
Description: A smartphone App about exercise will be installed in participants' mobile phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet about exercise
Description: A leaflet about exercise will be provided for the participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about diet
Description: Video about healthy diet will be played for the participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App about diet
Description: A smartphone App about healthy diet will be installed in participants' mobile phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet about diet
Description: A leaflet about healthy diet will be provided for the participants.
Study: NCT00116558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early NIPPV
Description: Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard NIPPV
Description: Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard NIPPV
Description: Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
Study: NCT03307733

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: walking and behavour change techniques
Description: a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
Study: NCT04626869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Diaphragm Movement
Description: Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Diaphragm Movement
Description: Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.
Study: NCT00829881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine Hydrochloride
Description: A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: A single placebo capsule
Study: NCT01232296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib
Description: 500 mg p.o. o.d. 5 days on/2 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg p.o. b.i.d.